Bundesamt für
Verbraucherschutz und
Lebensmittelsicherheit

Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)
Federal Office of Consumer Protection and Food Safety
Mauerstraße 39-42
10117 Berlin
(Germany)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Sensiblex 40 mg/ml
solution for injection for cattle

Date: 5 September 2017

MODULE 1

PRODUCT SUMMARY

EU Procedure number	DE/V/0163/001/DC
Name, strength and pharmaceutical form	**Fehler! Verweisquelle konnte nicht gefunden werden.**
Applicant	Veyx-Pharma GmbH Söhreweg 6 34639 Schwarzenborn GERMANY
Active substance(s)	Denaverine hydrochloride
ATC Vetcode	QG02CX90
Target species	Cattle
Indication for use	Cows, heifers: - Promotes dilation of the soft tissues of the birth canal in cases where the birth canal is insufficiently opened. - Regulates uterine contractions in animals with hypertonic muscular contractions of the uterus. Heifers: - Promotes dilation of the soft tissues of the birth canal to facilitate parturition.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original Decentralised procedure	26 April 2017
Date product first authorised in the Reference Member State (MRP only)	Not applicable
Concerned Member States for original procedure	AT, BG, CY, CZ, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, LV, MT, NL, PL, PT, RO, SI, SK, UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species cattle; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 40.0 mg/ml Denaverine hydrochloride (equivalent to 36.5 mg Denaverine) and the excipients Benzyl alcohol, Propylene glycol, Hydrochloric acid 10 % and Water for injections.

The container/closure system consists of sterile, colourless multi-dose glass containers of type I. The fill volumes are 10 ml and 50 ml.

The bottles are closed with sterile fluorinated bromobutyl rubber closures, and fixed with pre-sterilised aluminium caps. The glass containers are stored in respective cardboard boxes.

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is denaverine hydrochloride, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate product

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

The active substance is fully tested to ensure compliance with its specification immediately prior to its use in manufacture of the product.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 28 days stability after broaching is based on the demonstration of stability for a batch broached and stored 28 days at 30 °C ± 2°C.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is an auto-generic application according to Article 13(1) of Directive 2001/82/EC, and bioequivalence with a reference product has been demonstrated, safety studies are not required.
The pharmacological and toxicological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users and the environment.

Environmental Risk Assessment

Phase I

The environmental risk assessment can stop in Phase I because the initial predicted environmental concentration in soil (PECsoil-initial) is lower than 100 µg/kg for the active substance denaverine hydrochloride.

Conclusion

Based on the data provided, the ERA can stop at Phase I. The product is not expected to pose an unacceptable risk for the environment when used according to the SPC.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted as this is an auto-generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the identical reference product can be assumed.

MRLs

Denaverine hydrochloride is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	**Marker residue**	**Animal Species**	**MRL**	**Target tissues**	**Other provision**	**Therapeutic Classification**
Denaverine hydrochloride	NOT APPLICABLE	Bovine	No MRL required	NOT APPLICABLE	NO ENTRY	NO ENTRY

The excipients are listed in Table 1 of Commission Regulation (EU) No 37/2010 for all food producing species as substances for which no MRL is required. All substances are classified as harmless when used as excipients.

Withdrawal Periods

The following withdrawal periods are justified.

Cattle: Meat and offal: 1 day

Milk: 24 hours

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is an auto-generic application according to Article 13(1) of Directive 2001/82/EC, and bioequivalence with a reference product has been demonstrated, target animal safety and efficacy studies are not required. The target animal safety and efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).